Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

140.59USD
8 Dec 2017
Change (% chg)

$0.58 (+0.41%)
Prev Close
$140.01
Open
$140.00
Day's High
$140.74
Day's Low
$139.90
Volume
1,414,109
Avg. Vol
1,700,858
52-wk High
$144.34
52-wk Low
$109.93

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $377,697.81
Shares Outstanding(Mil.): 2,686.52
Dividend: 0.84
Yield (%): 2.39

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

Saddam Hussein at issue in 5th Circuit hearing in hip implant case

Johnson & Johnson argued before a federal appeals court on Thursday that a plaintiffs' lawyer improperly inflamed a jury that awarded $500 million in a hip implant case by suggesting the company had engaged in a range of unsavory conduct, including paying bribes to the regime of former Iraqi dictator Saddam Hussein.

Dec 08 2017

Drugmakers lose bid to dismiss Oklahoma's opioid lawsuit

An Oklahoma judge has denied a bid by drugmakers including Purdue Pharma LP and Johnson & Johnson to dismiss a lawsuit by the state's attorney general claiming the companies deceptively marketed opioid painkillers.

Dec 06 2017

Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

Dec 05 2017

UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

Dec 05 2017

CORRECTED-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks by its blockbuster drug Xarelto.

Dec 05 2017

Breakingviews - Consumer groups’ health drive comes at a cost

LONDON (Reuters Breakingviews) - Over-the-counter drugs could pose health risks for investors in consumer groups. Germany’s Merck has invited bids for its Seven Seas vitamins unit, while Pfizer is selling its more consumer-focused business. Nestlé and rivals see opportunities to apply their sharper marketing skills. But pumped-up valuations suggest the health drive will be expensive.

Dec 04 2017

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Dec 04 2017

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Dec 04 2017

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

Nov 30 2017

J&J loses bid to overturn $110 million talc cancer verdict

A Missouri state court judge has upheld a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

Nov 30 2017

Earnings vs. Estimates